ArticleTranslational cancer research2026
Comprehensive analysis of prognostic biomarkers for immunotherapy response in patients with advanced malignant melanoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of immunotherapy monotherapy is limited in Chinese patients with melanoma. The aim of this study was to evaluate the prognostic biomarkers in patients with advanced or unresectable malignant melanoma receiving immunotherapy, to identify high-risk subgroups and improve survival stratification. Methods: We retrospectively reviewed the records of 62 patients pathologically diagnosed with advanced or unresectable melanoma from February 2019 to October 2022 at Nanjing Drum Tower Hospital and treated with immunotherapy. The complete basic information of patients was collected through medical history review and follow-up, including age, gender, primary tumor site, subtype, stage, metastatic site, and treatment lines. Next-generation sequencing (NGS) of tumor tissue samples was conducted. Hematological specimens were collected before the first immunotherapy session to calculate the neutrophil-to-lymphocyte ratio (NLR) and albumin levels. Results: Greater than five metastatic sites, liver metastases, bone metastases, an NLR ≥3, and abnormal albumin levels were associated with shorter progression-free survival (PFS) in patients treated with immunotherapy, and patients who received combination with chemotherapy had better survival. The most commonly altered genes included Conclusions: NLR ≥3 and the presence of liver metastases were identified as independent prognostic factors. These preliminary findings may help refine prognostic stratification for advanced melanoma patients receiving immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.